The power of care

Annual Report 2025

Facts, figures, and hightlights

Download the full report
Helen Giza

Letter to our shareholders

CEO Helen Giza summarizes our performance in 2025, our strategy, and our efforts to drive long-term growth.

Learn more

Key figures

2025
 

19.63

Revenue in € BN

1.25

Net income1 excl. special items in € BN

1.49

Dividend per share in €2

109,698

Employees3

291,902

Patients

73

Patient Net Promoter Score

29%

Reduced scope 1 and market-based scope 2 CO2e emissions footprint compared to 2020

1 Net income attributable to shareholders of Fresenius Medical Care AG.
2 2025: Proposal to be approved by the Annual General Meeting on May 21, 2026.
3 Headcount

2024
 

19.34

Revenue in BN (€)

0.90

Net Income1 excl. special items in € BN

1.44

Dividend per share in €

111,513

Employees3

299,352

Patients

72

Patient Net Promoter Score

25%

Reduced scope 1 and market-based scope 2 CO2e emissions footprint compared to 2020

Results of operations

Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in 2025.

Learn more about our results of operations

Sustainability

Future-proofing exceptional kidney care by advancing patient care, driving sustainable operations, and empowering our people to contribute to a sustainable future.

Learn more about our sustainability performance


Our 2025 highlights – It’s all about people

Advancing kidney care: Introducing high-volume hemodiafiltration to the U.S.

Read more

Research round-up: Innovation that moves kidney care forward

Read more

Media center
See all stories
No Results Found
See all stories
PREVIOUS
    NEXT
    Events
    See all events
    No Results Found
    See all events
    PREVIOUS
      NEXT
      Contact
      Country websites

      All contact information

      Social Media

      © Fresenius Medical Care AG 2026

      Privacy policy

      Cookie settings

      Imprint